(Q30369026)

English

Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

0 references

Deborah L. Birx

6

object named as

Deborah L Birx

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Francine E McCutchan

8

object named as

Francine E McCutchan

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Eric Sanders-Buell

3

object named as

Eric Sanders-Buell

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

5

object named as

Merlin L Robb

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

7

object named as

Nelson L Michael

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Victoria R Polonis

9

object named as

Victoria R Polonis

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Lindsay Wieczorek

2

object named as

Lindsay Wieczorek

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

author name string

Bruce K Brown

1

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Andrew Rosa Borges

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work or name

0 references

publication date

22 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

375

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

529-538

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

HIV vaccine design and the neutralizing antibody problem

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Determining neutralization serotypes of HIV type 1 by neural networks

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Diversity of the human immunodeficiency virus type 1 envelope glycoprotein in San Francisco Men's Health Study participants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

HIV vaccine strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Quantitative infectivity assay for HIV-1 and-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Bioorganic approaches towards HIV vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Mechanisms contributing to the neutralization of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.02.022

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2008.02.022

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30369026&oldid=1755125702"